Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.34 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900082 | 0.90 | PTGER4 (0.38) | PTGER4UGCGCXCR5 | |
| SCHEMBL1899668 | 0.86 | CETP (0.38) | MAPK14UGCG | |
| SCHEMBL1900140 | 0.86 | CXCR5 (0.45) | MAPK14PTGER4UGCGMEN1KMT2A | |
| SCHEMBL2139706 | 0.85 | OPRM1 (0.37) | PTGER4UGCGCXCR5MTTP | |
| SCHEMBL5751951 | 0.84 | PTGER4 (0.40) | PTGER4UGCGCNR1PPARG | |
| SCHEMBL5751536 | 0.82 | PTGER4 (0.38) | PTGER4UGCGMEN1KMT2A | |
| SCHEMBL5753971 | 0.80 | CETP (0.36) | UGCG | |
| SCHEMBL5752724 | 0.80 | PTGER4 (0.35) | PTGER4CXCR5 | |
| SCHEMBL5751913 | 0.80 | CETP (0.34) | PTGER4UGCG | |
| SCHEMBL5753406 | 0.80 | CETP (0.38) | UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | claimed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | claimed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| US-7897175-B2 | Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); two drugs are separate from each other; improved chemical stability of the HMG-CoA reductase inhibitor | BEND RESEARCH, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1961419-B1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1961419-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | Pfizer Products Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1581210-B1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PROD INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1653926-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| EP-1581210-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578415-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | PFIZER INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| WO-2004056358-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056396-A1 | DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | MAPK14 4078/4885PTGER4 2003/4885UGCG 1338/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | MAPK14 3182/4885PTGER4 1632/4885UGCG 740/4885 |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | MAPK14 4233/4885PTGER4 2970/4885UGCG 1100/4885 |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, CHLSN | MAPK14 4521/4885PTGER4 2907/4885UGCG 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.